Qiagen vs Repligen
QGEN and RGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QGEN and RGEN compare
Repligen grew revenue faster over the last twelve months (13.8% versus 5.7% for Qiagen).
Qiagen keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −1.5% at Repligen.
Qiagen scores higher on the StockData Score (10 against 7 for Repligen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QGEN | RGEN |
|---|---|---|
| Size and price | ||
| Market cap | – | $10.0B |
| Share price | $50.22 | $176.94 |
| Change, 1 year | 1.1% | 19.2% |
| Change, 5 years | −12.0% | −33.7% |
| Beta (5Y) | 0.69 | 1.50 |
| Employees | 5,700 | 2,000 |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 12.4× |
| P/B | – | 4.8× |
| EV/EBITDA | – | 94.9× |
| P/FCF | – | 93.6× |
| FCF yield | – | 1.1% |
| Fair value | – | $79.82 |
| Margin of safety | – | −122% |
| Growth | ||
| Revenue growth (TTM) | 5.7% | 13.8% (better) |
| Revenue growth, 5Y average | 2.2% | 15.0% (better) |
| Net income growth (TTM) | 408% (better) | −779% |
| EPS growth (TTM) | 424% | – |
| EPS growth, 5Y average | 4.9% (better) | −5.0% |
| Profitability | ||
| Gross margin | 62.2% (better) | 53.5% |
| Operating margin | 22.3% (better) | 2.3% |
| Net margin | 20.3% (better) | −1.5% |
| FCF margin | 21.7% (better) | 13.2% |
| Return on equity | 11.6% (better) | −0.57% |
| Return on invested capital | 9.9% (better) | 0.71% |
| Financial health | ||
| Debt / equity | 0.44 | – |
| Net debt / EBITDA | 0.84 | – |
| Interest coverage | 14.0× (better) | 0.8× |
| Current ratio | 3.90 | 9.88 (better) |
| Altman Z-score | – | 8.14 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Payout ratio | 12.8% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 67.4% | 117% |
| Held by insiders | 0.00% | 0.67% |
| Insider net buying, 12 months | – | −$14.2M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 3.5% | 13.5% |
Go deeper
- QGEN stock overview
- QGEN income statement
- QGEN valuation and score
- RGEN stock overview
- RGEN income statement
- RGEN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.